Study: I-TEAM: Intervention Trial in Early Age-related Macular DegenerationSponsor: Newtricious R&D BVPurpose: To assess whether there is a change in visual function and status of the retina after a year of intervention in subjects with early signs of age-related macular degenerationDesign: Randomized, Efficacy, Parallel Assignment, Double-blind, TreatmentNumber of Patients:120Inclusion Criteria: many small drusen, or a few intermediate-sized (63-124 micrometres in diameter) drusen, or macular pigmentary changesExclusion Criteria: ocular media opacity (severe cataract); history of active small bowel disease or resection; atrophic gastritis; hyperlipidemia (LDL >120 mg/dL or triglycerides >400 mg/dL)Information: ian.j.murray@manchester.ac.uk

Study: A Safety Study of CNTO 2476 in Patients With AMDSponsor: Janssen Research & DevelopmentPurpose: To evaluate the safety and tolerability of CNTO 2476 administered subretinallyDesign: Randomized, Safety/Efficacy, Single Group Assignment, Open Label, TreatmentNumber of Patients: 56Inclusion Criteria: Bilateral GA of the macula caused by AMDExclusion Criteria: Exudative AMD; evidence of other significant ophthalmologic disease; ocular hypertension; previous cell therapy other than blood componentsInformation: JNJ.CT@sylogent.com

Study: Fluocinolone Acetonide Intravitreal Inserts in Geographic AtrophySponsor: AlimeraPurpose: To compare the safety and efficacy of Medidur FA treatment in one eye to the sham-treated fellow eye of subjects with geographic atrophy secondary to AMDDesign: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blindNumber of Patients: 40Inclusion Criteria: Bilateral GA secondary to AMD of ≥0.5 and ≤7 disc areasExclusion Criteria: GA secondary to any condition other than AMD in either eye; history of or current CNV or need for anti-angiogenic therapy; glaucoma or ocular hypertensionInformation: lschulz@med.wayne.edu

Study: Study of Human Central Nervous System Stem Cells (HuCNS-SC) in AMDSponsor: StemCells, Inc.Purpose: To investigate the safety and preliminary efficacy of unilateral subretinal transplantation of HuCNS-SC cells in subjects with geographic atrophy secondary to AMDDesign: Interventional, Safety/Efficacy, Single Group Assignment, Open Label, TreatmentNumber of Patients: 16Inclusion Criteria: Diagnosis of AMD with GA; only patients with a speciic degree and extent of GA will be eligibleExclusion Criteria: Prior vitreal or retinal surgery; glaucoma; atrophic macular disease of any other cause; diabetic retinopathy or DMEInformation: kglocke@retinafoundation.org

Study: Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry AMD Including GASponsor: PfizerPurpose: To determine the safety and tolerability of multiple doses of RN6G in subjects with advanced dry, AMD including GADesign: Randomized, Pharmacokinetics, Single Group, Double-blind, TreatmentNumber of Patients: 24Inclusion Criteria: Diagnosis of dry AMD including uni- or multi-focal GA without foveal involvement; BCVA of 20/50 or betterExclusion Criteria: Ocular disease other than advanced AMD or GA in the study eye; history or diagnosis of exudative AMD, with subretinal or CNV lesions; medications known to be toxic to the lens, retina or optic nerveInformation: (800) 718-1021

Study: Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With GA Secondary to AMDSponsor: GlaxoSmithKlinePurpose: To determine the safety and efficacy of GSK933776 in the treatment of GA secondary to AMDDesign: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blindNumber of Patients: 162Inclusion Criteria: Evidence of AMD confirmed by the presence of at least 1 drusen ≥125 microns; well-demarcated GA due to AMD Exclusion Criteria: Additional eye disease that could compromise assessment of BCVA or imaging of the posterior pole; history of CNV; previous treatment for AMD, with the exception of dietary supplementsInformation: GSKClinicalSupportHD@gsk.com

Study: Safety and Tolerability of Subretinal Transplantation of hESC-derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry AMDSponsor: Advanced Cell TechnologyPurpose: To evaluate the effect of subretinal injection of human embryonic stem cell-derived RPE cells in patients with dry AMD and to perform exploratory evaluation of potential efficacy endpoints to be used in future studies of RPE cellular therapyDesign: Interventional, Safety, Single-group Assignment, Open LabelNumber of Patients: 12Inclusion Criteria: Advanced dry AMD with evidence of one or more areas of > 250 microns of GA involving the central foveaExclusion Criteria: Presence of active or inactive CNV; presence or history of other retinal vascular or degenerative disease other than AMD; history of optic neuropathyInformation: schwartz@jsei.ucla.edu

Study: NVAMD: Neovascular Age-related Macular DegenerationSponsor: Oregon Health and Science UniversityPurpose: To assess the utility of OCT angiography in the evaluation of NVAMDDesign: Observational, Case Control, ProspectiveNumber of Patients: 15Inclusion Criteria: Presence of Neovascular AMD confirmed by fluorescein dye leakage on angiogram or presence of at least one of the following on OCT: subretinal fluid, intraretinal fluid, or sub-retinal pigment epithelial fluid; treatment naïve group consists of individuals who have not received any treatment for neovascular AMD in the study eye; votive treatment group consists of individuals who have received treatment with an anti-VEGF agent (Avastin, Lucentis, Macugen, or Eylea) 6 weeks prior enrollment visitExclusion Criteria: Inability to maintain stable fixation for OCT imaging; significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant; a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control); blood pressure > 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible; prior macular laser treatment; Subretinal hemorrhage or fibrosis >50% of choroidal neovascular lesion Visual acuity 20/200 or worse; an ocular condition is present such that, in the opinion of the investigator, may alter the retinal anatomy (eg: epiretinal membrane); an ocular condition is present (other than Neovascular AMD) that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, etc.)Information: (503) 494-3000

Study: RE-VIEW: Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular AMD Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)Sponsor: RegeneronPurpose: To evaluate the efficacy and safety of Intravitreal Aflibercept Injection (IAI) administered over 2 years , and to provide clinical information from the first year in the trial evaluating the adverse effects, if any, on the corneal endothelium following administration of IAIDesign: Interventional, Safety/Efficacy, Single Group, Open Label, TreatmentNumber of Patients: 150Inclusion Criteria: Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye; the CNV area must be at least 50% of total lesion sizeExclusion Criteria: Exudative AMD in the fellow eye; corneal endothelial measures as judged by an independent reading center; any prior use of intraocular anti-VEGF treatment for neovascular AMD in either eyeInformation: clinicaltrials@regeneron.com

Study: ATLAS: Repeated Eye Injections of Aflibercept for Treatment of Wet AMDSponsor: Brian Burke, MPH/RegeneronPurpose: To evaluate the visual outcome and number of injections required during an OCT-guided treat and extend regimen with intravitreal aflibercept for treatment of subfoveal neovascular AMDDesign: Interventional, Nonrandomized, Parallel Assignment, Open Label, Treatment Number of Patients: 40Inclusion Criteria: Only one eye for each patient demonstrating a pre-treatment acuity of 20/25 - 20/320 is eligible; patients cannot have concurrent progressive retinal diseaseExclusion Criteria: Prior treatment for NVAMD in the study eye; prior experimental treatment of NVAMD; prior treatment with systemic anti-VEGF agents; prior treatment with verteporfinInformation: research@midatlanticretina.com

Study: Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular AMDSponsor: GenzymePurpose: To examine the safety and tolerability of an experimental gene transfer agen in patients with Neovascular AMDDesign: Interventional, Nonrandomized, Safety, Parallel Assignment, Open Label Number of Patients: 34Inclusion Criteria: CNV secondary to AMD, as confirmed by the patient’s medical history and a documented diagnosis of CNV; distance BCVA of 20/100 or worseExclusion Criteria: CNV in the study eye due to any reason other than AMD; history of conditions in the study eye during Screening which might alter visual acuity or interfere with study testingInformation: medinfo@genzyme.com

Study: Genetic Load and Phenotype in Aggressive AMD (RPED Genetics)Sponsor: Sequenom, Inc.Purpose: To examine cheek cell samples to determine if there is a correlation between genotype (DNA markers) and phenotype (the type of AMD the patient has)Design: Observational, Cohort, ProspectiveNumber of Patients: 100Inclusion Criteria Subject agrees to provide two buccal swabs in accordance with this protocolExclusion Criteria: Previous sample donation under this protocol; presence of retinal disease involving the photoreceptors and/or outer retinal layers other than AMD loss which have been present prior to age 50Information: (415) 923-3482

Study: Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) AMDSponsor: Ohr Pharmaceuticals, Inc.Purpose: To evaluate the safety and efficacy of topical squalamine lactate eye drops in treating patients with neovascular AMDDesign: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blindNumber of Patients: 120Inclusion Criteria: A diagnosis of CNV secondary to AMD with total lesion area ≤ 12 disc areas with CNV affecting at least 50% of the total lesion area confirmed by FAExclusion Criteria: Neovascularization secondary to any condition other than AMD in the study eye; blood occupying greater than 50% of the AMD lesionInformation: itaraporewala@ohrpharmaceutical.com

Study: T-REX: Treat and Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg RanibizumabSponsor: Charles C. Wykoff, MD, PhD/GenentechPurpose: To maintain an exudation-free macula with the fewest number of office visits, tests and injectionsDesign: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Open Label, TreatmentNumber of Patients: 60Inclusion Criteria: Any CNVM lesion secondary to AMD; BCVA in the study eye between 20/32 and 20/400; the total area of subretinal hemorrhage and fibrosis must comprise less than 50% of the total lesionExclusion Criteria: Subretinal hemorrhage in the study involving the center of the foveaInformation: karri.schuetzle@houstonretina.com

Study: Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging (PVOCT)Sponsor: University of California, San FranciscoPurpose: To determine whether phase variance optical coherence tomography (PVOCT), a software-based OCT image processing technology, can be used to generate angiographic images of the retinochoroidal vasculature that are comparable to those produced by fluorescein angiographyDesign: Observational, Cohort, ProspectiveNumber of Patients: 78Exclusion Criteria: Any patients with ocular media opacities which prevent clear evaluation of the fundus by either FA or OCTInformation: smcclint@gmail.com

Study: Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)Sponsor: Sequenom, Inc.Purpose: To determine if there is an association between genetics, MPOD and the risk of progression to wet AMDDesign: Observational, Cohort, ProspectiveNumber of Patients: 150Inclusion Criteria Subject is diagnosed with either CNV, dry AMD or is an age-matched control; self-reported as non-Hispanic CaucasianExclusion Criteria: Previous donationInformation: jmcavinue@morriseyegroup.com

Study: Nexus: Efficacy and Safety Study of iSONEP With and Without Lucentis/Avastin to Treat AMDSponsor: Lpath, Inc./PfizerPurpose: To determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis or Avastin in subjects with wet AMDDesign: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blindNumber of Patients: 160Inclusion Criteria Subjects who have received 3-10 IVT injections of Lucentis or Avastin within 12 months prior to screening; active subfoveal CNV secondary to AMDExclusion Criteria: Most recent IVT injection of Lucentis or Avastin <28 days and >65 days prior to screening; previous PDT or Macugen at any time point; focal thermal laser or grid laser within 3 months prior to Day 0Information: info@lpath.com

Study: Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Macular Degeneration Previously Treated With Ranibizumab or BevacizumabSponsor: Cleveland Clinic/RegeneronPurpose: To examine the use of Aflibercept in patients with exudative macular degeneration requiring intravitreal injectionsDesign: Observational, Case-only, ProspectiveNumber of Patients: 25Inclusion Criteria: Active primary subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by historical OCTs and angiogramsExclusion Criteria: Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye, except dietary supplements or vitaminsInformation: singhr@ccf.org

Study: Retinal and RPE Autoimmunity in AMD - Correlation With Lucentis Therapy (Antibody)Sponsor: Lawrence S. Morse, MD/GenentechPurpose: To determine if “wet” AMD patients differ from patients with “dry” AMD or normal eyes in the production of anti-RPE or anti-retinal antibody formationDesign: Interventional, Nonrandomized, Parallel Assignment, Open Label, TreatmentNumber of Patients: 131Inclusion Criteria: Patients with active neovascular AMD naïve to treatment or treated with 4 or more monthly injections of anti-VEGF treatment without responseExclusion Criteria: Concurrent eye disease in the study eye that could compromise visual acuity; previous AMD therapy; patients being treated with immunomodulatory drugsInformation: lsmorse@ucdavis.edu

Study: Safety and Efficacy of Intravitreal LFG316 in Wet AMDSponsor: NovartisPurpose: To assess the safety and efficacy of LFG316 in patients with AMDDesign: Randomized, Parallel Assignment, Single-blind, TreatmentNumber of Patients: 57Inclusion Criteria: BCVA of 60 letters or less in the study eye; an active CNV membrane attributable to neovascular AMDExclusion Criteria: History of recurrent non-response to anti-VEGF therapy; retinal disease other than AMD; CNV not due to AMDInformation: (862) 778-8300

Study: Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative AMDSponsor: Stanford UniversityPurpose: To determine whether patients who have switched from ranibizumab to VEGF Trap-Eye have comparable resultsDesign: Observational, Cohort, ProspectiveNumber of Patients: 590Inclusion Criteria: Established diagnois of exidative AMD who have been switched from ranibizumab to VEGF Trap-EyeExclusion Criteria: Previous or concurrent history of treatment of other retinal diseases with agents other than ranibizumabInformation: (650) 723-6995

Study: Addition of 20 mg/Day Zeaxanthin to Triple Therapy Treatment Options for AMDSponsor: The Retina Center of St. Louis County, P.C./ZeaVision, Inc.Purpose: To evaluate whether 20 mg per day of oral zeaxanthin as a supplement to patients with CNV and exudative AMD undergoing combination therapy with bevacizumab, dexamethasone and PDT laser photocoagulation improves outcomesDesign: Observational, Case Control, RetrospectiveNumber of Patients: 200Inclusion Criteria: Subjects must have AMD with a CNV membrane either classic or occult in at least one eye; preoperative BCVA equal to or greater than 19 lettersExclusion Criteria: Retinal disease not AMDInformation: rjolk@retina-stl.com

Study: Evaluation of AGN-150998 in Exudative AMDSponsor: AllerganPurpose: To assess the safety of AGN-150998 administered as an intravitreal injection to patients with exudative AMDDesign: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blind, TreatmentNumber of Patients: 200Inclusion Criteria: AMD; BCVA between 20/40 and 20/320Exclusion Criteria: Nearsightedness of 8 D or more; history of or current glaucoma in the study eye; cataract surgery or Lasik within the last 3 monthsInformation: clinicaltrials@allergan.com

Study: COMPASS: Clinical Assessment Of AMD Patients After Early Diagnosis and Treatment With RanibizumabSponsor: UC, San Diego/GenentechPurpose: To determine if patients treated early after diagnosis of wet AMD can return/maintain to their baseline predisease BCVADesign: Intervention, Safety/Efficacy, Single-group Assignment, Open Label, TreatmentNumber of Patients: 40Inclusion Criteria: Naïve wet-AMD within 4 months of disease onset for GALLEY patients and within 3 months of disease onset for all others; patients that have lost > 5 letters from baseline best vision; BCVA 20/25-20/320Information: CJL015@ucsd.edu

Study: Study of Dark Adaptation in AMDSponsor: National Eye InstitutePurpose: To evaluate the effectiveness of using a dark adaptation protocol to identify and monitor early to middle dry AMDDesign: Observational, ProspectiveNumber of Patients: 200Inclusion Criteria: Group 0: No large drusen or advanced AMD; Group 1: At least one large drusen in the study eye and no large drusen or advanced AMD in the fellow eye; Group 2: Bilateral large drusen with or without RPE hypo/hyperpigmentary changes; Group 3: At least one large drusen in the study eye and advanced AMD in the fellow eyeExclusion Criteria: Advanced AMDInformation: prpl@mail.cc.nih.gov

Study: CFH&AMD: Complement Factor H Haplotypes and Smoking in AMDSponsor: Department of Veterans AffairsPurpose: To test the hypothesis that smoking increases AMD by increasing complement activation and that this is positively correlated with known disease variations in the CFH geneDesign: Observational, Cohort, ProspectiveNumber of Patients: 300Exclusion Criteria: Ocular diseases that might simulate AMD or preclude its diagnosisInformation: rohrer@musc.edu

Study: Tools to Optimize Patient Presentation After Onset of Exudative AMDSponsor: Johns Hopkins UniversityPurpose: To demonstrate that use of the test booklet leads to more rapid identification of newly developing vision problems, earlier diagnosis and treatment of incipient wet AMD that should result in fewer people losing their vision and less severe losses of visionDesign: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Open Label, DiagnosticNumber of Patients: 1000Inclusion Criteria: Subjects with a confirmed diagnosis of AMD in at least one eye will be recruited for components 1 and 2 of the studyExclusion Criteria: Subjects with vision loss due to ocular pathology other than AMDInformation: gdagnelie@jhmi.edu

DIABETIC MACULAR EDEMA

Study: Dextromethorphan for Diabetic Macular EdemaSponsor: National Eye InstitutePurpose: To see if dextromethorphan can help treat diabetic macular edemaDesign: Interventional, Safety/Efficacy, Single Group, Open Label, TreatmentNumber of Patients: 8Inclusion Criteria: BCVA ETDRS score of 34 letters or better (i.e., 20/200 or better) Definite retinal thickening due to diabetic macular edema based on clinical examination that is not refractory to further therapy as based on the investigator’s clinical judgment; retinal thickening due to DME within 3000 microm of the center of the macula, as measured by Spectral OCT; media clarity, pupillary dilation and patient cooperation sufficient for adequate fundus photographsExclusion Criteria: An ocular condition is present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular edema (e.g., foveal atrophy, pigmentary changes, dense subfoveal hard exudates, non-retinal condition); an ocular condition is present (other than DR) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, etc.); substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by three lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal); history of panretinal scatter photocoagulation (PRP) within four months prior to study entryInformation: meg.gordon@nih.gov

Study: ROTATE: Ranibizumab For Persistent Diabetic Macular Edema After BevacizumabSponsor: Southeast Retina Center, Georgia/GenentechPurpose: To determine the safety and efficacy of intravitreally administered 0.3mg ranibizumab in subjects with persistent Diabetic Macular Edema (DME) after recent and frequent bevacizumab (at least 2 bevacizumab intravitreal injections within 2 months prior to enrollment and at least 6 bevacizumab injections within 9 months of enrollment)Design: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Open Label, TreatmentNumber of Patients: 30Inclusion Criteria: Central-involved DME in study eye (OCT CSF >=275um on Heidelberg Spectralis spectral domain OCT with evidence of intraretinal or subretinal fluid or cysts); deflnite retinal thickening due to diabetic macular edema involving the center of the macula; media clarity, pupillary dilation and individual cooperation for adequate fungus photography and fluorescein angiography; VA score in study eye <=80 and >=20 (approximate Snellen equivalent 20/25 to 20/400)Exclusion Criteria: Known allergy to ranibizumab; acute cardiovascular event requiring hospitalization within the past 3 months; systemic anti-VEGF or pro-VEGF treatment within 3 months prior to randomization or anticipated use during the study; macular edema is considered to be due to a cause other than DME; an ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from the resolution of macular edemaInformation: dmarcus@southeastretina.com

Study: Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy SurgerySponsor: Lahey ClincPurpose: To assess the safety and efficacy of Ozurdex after vitrectomyDesign: Randomized, Safety/Efficacy, Single-group Assignment, Double-blind, TreatmentNumber of Patients: 15Inclusion Criteria: Patients with DME secondary to diabetes mellitus involving the center of the macula OCT thickness is > 300 microns with intraretinal cystic edema; BCVA between 20/40 to 20/400; patient had vitrectomy surgeryExclusion Criteria: Patient unlikely to benefit from intravitreal Ozurdex due to macular ischemia, atrophy, or other condition; patient with history of steroid response with IOP >35 mm Hg or requirement to be on > 2 glaucoma medications following previous steroid injection; previous injection of anti-VEGF or steroid in the study eye within 90 days; vitrectomy, cataract surgery, or YAG capsulotomy within 90 daysInformation: avon.p.stewart@lahey.org

Study: CDDR: Computer Detection of Diabetic Retinopathy Compared to Clinical ExaminationSponsor: IDx LLCPurpose: To determine whether computer detection of the severity of diabetic retinopathy including the presence of clinically significant macular edema is not inferior to the detection using a dilated eye examination by a Board-certified ophthalmologistDesign: Observational, Case-only, ProspectiveNumber of Patients: 600Inclusion Criteria: No history of any other retinal vascular disease, glaucoma, or other disease that may affect the appearance of the retina or optic disc (refractive error and ocular surface disease are allowed); other than cataract surgery, no history of intraocular surgery, ocular laser treatments for any retinal disease, or ocular injections for diabetic macular edema or proliferative disease; no media opacity precluding good retinal photographyExclusion Criteria: a history of retinal vascular disease other than due to diabetic retinopathy, glaucoma, or other disease that may affect the appearance of the retina or optic disc; previous intraocular surgery other than cataract; previous laser to the retina; or previous intraocular injections for the treatment of diabetic retinopathy; a media opacity in either eye that is severe enough to preclude good retinal photographyInformation: (713) 559-5200

Study: Protocol T: Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for DMESponsor: DRCR.net/NEI/Genentech/RegeneronPurpose: To compare the efficacy and safety of (1) intravitreal aflibercept, (2) intravitreal bevacizumab, and (3) intravitreal ranibizumab when given to treat central-involved DME in eyes with visual acuity of 20/32 to 20/320Design: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Single-blind, TreatmentInclusion Criteria: BCVA between 20/32 and 20/320 within eight days of randomization; definite retinal thickening due to DME involving the center of the macula; DME present on OCT, within eight days of randomizationExclusion Criteria: Macular edema is considered to be due to a cause other than DME; macular edema considered to be related to ocular surgery; vitreoretinal interface abnormalities are the primary cause of macular edemaInformation: (863) 682-7474

Study: Ranibizumab and Bevacizumab for Diabetic Macular EdemaSponsor: National Eye InstitutePurpose: To compare the effectiveness of ranibizumab and bevacizumab injections for diabetic macular edemaDesign: Interventional, Randomized, Safety/Efficacy, Crossover Assignment, Double-blind, Treatment Number of Subjects: 60Inclusion Criteria: Eye has a BCVA ETDRS score between 20/32 and 20/400; eye has definite retinal thickening or cystic changes due to DME based on clinical exam involving the center of the macula that is not refractory to further therapy as based on the investigator’s clinical judgment; eye has retinal thickness in the central subfield on baseline OCT measurement greater than or equal to 330 microns, as measured by Cirrus OCTExclusion Criteria: Eye has an ocular condition present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular edema (e.g., foveal atrophy, pigmentary changes, dense subfoveal hard exudates, non-retinal condition); eye has an ocular condition present (other than DR) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, etc.)Information: wileyhe@mail.nih.gov

Study: Safety and Pilot Efficacy of AKB-9778 in Subjects With DMESponsor: Aerpio TherapeuticsPurpose: To evaluate the safety, pharmacokinetics, pharmacodynamics, and pilot efficacy of multiple ascending dose levels of AKB-9778 given as subcutaneous injections daily for 28 days in patients with DMEDesign: Interventional, Safety, Single Group Assignment, Open Label, TreatmentNumber of Patients: 24Inclusion Criteria: Decrease in vision determined to be primarily the result of DME in the study eye; definite retinal thickening due to diffuse DME involving the center of the macula in the study eye; mean central subfield thickness of at least 325 microns by OCT in the study eye.Exclusion Criteria: Panretinal scatter photocoagulation (PRP) or focal laser within 12 weeks prior to Screening; prior pars plana vitrectomy within 12 weeks prior to Screening; any ocular surgery within 12 weeks prior to Screening; YAG capsulotomy within 7 days prior to ScreeningInformation: kpeters@aerpio.com

Study: iDEAL: Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of DMESponsor: Quan Dong Nguyen/Juvenile Diabetes Research Foundation/iCo Therapeutics, Inc.Purpose: To assess the safety of repeated iCo- 007 intravitreal injections in treatment of subjects with diabetic macular edema as monotherapy and in combination with ranibizumab or laser photocoagulationDesign: Interventional, Randomized, Safety/Efficacy, Factorial Assignment, Open LabelNumber of Patients: 208Inclusion Criteria: Have diabetes mellitus type I or II (insulin or non-insulin dependent) with HbA1c ≥ 5.5% and HbA1c ≤13%; have non-proliferative diabetic retinopathy, or inactive proliferative diabetic retinopathy, or proliferative diabetic retinopathy with a reasonable expectation that panretinal photocoagulation will not be required during the study follow-up period; have diabetic macular edema with central subfield thickness of ≥ 250 microns (confirmed by Stratus TD OCT) Have best-corrected visual acuity (ETDRS) that is Snellen equivalent of 20/32 and ≥ 20/320, inclusiveExclusion Criteria: Have macular or perimacular edema secondary to an etiology other than diabetes; have concurrent retinal diseases other than diabetic retinopathy; have additional ocular diseases compromising visual acuity and/or interfering with study assessmentsInformation: qnguyen4@jhmi.edu

Study: Ozurdex for Treatment of Recalcitrant Diabetic Macular EdemaSponsor: Retina Macula Institute/AllerganPurpose: To test the efficacy of a 0.7 mg intravitreal dexamethasone implant on macular leakage and VA for patients with recalcitrant DMEDesign: Interventional, Randomized, Efficacy, Parallel Assignment, Single-blind, TreatmentNumber of Patients: 20Inclusion Criteria: Presence of NPDR or PDR as confirmed by FA; prior treatment with ≥ 2 intravitreal anti-VEGF injections but no treatment in last 4 weeks; < 0.1 Log OCT decrease in macular edema on high resolution OCT between initial visit and following treatment with ≥2 anti-VEGF injectionsExclusion Criteria: Injection of steroid medication within prior 3 months; evidence of significant GA on fluorescein angiography in the opinion of the treating physician; concurrent ocular disease that would limit visual acuityInformation: gina.kim@retinamaculainstitute.com

Study: DAVE: Efficacy and Safety Trial of Intravitreal Injections Combined With PRP for the Treatment of CSME Secondary to Diabetes MellitusSponsor: Genentech/Greater Houston RetinaPurpose: To study the efficacy and safety of ranibizumab injection monotherapy verses a duel therapy of 0.5 mg ranibizumab combined with ultrawide, 200° fleld angiography guided panretinal photocoagulation in patients with CSME-CI secondary to diabetes mellitusDesign: Interventional, Randomized, Safety/Efficacy, Single Group, Open Label, Treatment Number of Patients: 40Inclusion Criteria: BCVA of 20/32 to 20/200; high-definition OCT central thickness measurement of ≥ 300μm; decrease in VA determined to be the result of DMEExclusion Criteria: Prior ocular treatment; history of vitrectomy surgery in the study eye; any panretinal photocoagulation in the study eye; prior treatment with intraocular or subconjunctival steroids in the study eye 4 months prior to screening.Information: dmbmd@houstonretina.com

Study: Dosing Study of Ranibizumab for Diabetic Retinal and Macular EdemaSponsor: Retina Vitreous Associates of Florida/GenentechPurpose: To determine whether treating diabetic retinal swelling with ranibizumab injections into the eye monthly is better than ranibizumab injections into the eye less frequentlyDesign: Randomized, Safety/Efficacy, Parallel Assignment, Open Label, TreatmentNumber of Patients: 20Inclusion Criteria: Patients will have met standard, accepted diagnostic criteria for diabetes and will be currently treated with at least one systemic antihyperglycemic or insulin medication; BCVA less than or equal to 20/40; central foveal thickness of >300μmExclusion Criteria: Intraocular surgery less than 6 months ago; ERM of clinical signiflcance; prior vitrectomy; uncontrolled glaucomaInformation: (727) 323-0077

Study: Near-infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot StudySponsor: Medical College of WisconsinPurpose: To determine the effects of short term (3 month) near-infrared light therapy on anatomic and functional abnormalities of DME as assessed by VA, OCT multifocal electroretinography and fundus bimicroscopyDesign: Interventional, Nonrandomized, Safety/Efficacy, Single-group Assignment, Open LabelNumber of Patients: 20Inclusion Criteria: Fellow eye meets criteria; able to successfully tolerate a 3-month deferral of laser photocoagulationExclusion Criteria: Significant renal disease, deined as a history of chronic renal failure requiring dialysis or kidney transplant; subjects in poor glycemic control who, within the last 4 months, initiated intensive insulin treatment or plan to do soInformation: hwhelan@mcw.edu

Study: Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without DMESponsor: NEI/NIH Clinical CenterPurpose: To investigate genetic factors that may influence the development of DMEDesign: Observational, ProspectiveNumber of Patients: 400Inclusion Criteria: Participant is diagnosed with active DME deined by luorescein leak-age associated with either central retinal thickness greater than 260 microns on spectral domain OCT or cystic changes present on OCT; or participant has evidence of focal laser scars indicative of prior DME Investigators will verify the laser therapy was performed for DME via medical records, FA or photographsExclusion Criteria: Another retinal disease that may confound the evaluation of the DME; participant has opacities of the ocular media, or other problems sufficient to preclude adequate dilated examinationInformation: (800) 411-1222

Study: GEM: Phase I Dose Escalation Safety Study of RetinoStat in Advanced AMDSponsor: Oxford BioMedicaPurpose: To examine the safety of an experimental gene transfer agent, RetinoStat, designed to treat neovascular AMDDesign: Interventional, Safety, Single-group Assignment, Open Label, TreatmentNumber of Patients: 18Inclusion Criteria: Clinical diagnosis of AMD with active CNV that shows evidence of leakage; BCVA less than or equal to 20/200Exclusion Criteria: Significant ocular abnormalities that prevent retinal assessment; treatment with steroids within three months of screening; treatment with anti-VEGF therapy within one month of screeningInformation: pcampo@jhmi.edu

Study: A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug)in the Treatment of Diabetic Macular EdemaSponsor: Ampio PharmaceuticalsPurpose: To evaluate the efficacy of ultra low dose danazol (Optina) for the treatment of diabetic macular edema versus placeboDesign: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blind, TreatmentNumber of Patients: 450Inclusion Criteria: Stable diabetic and metabolic control (no major changes in diabetic or lipid reducing medications for 3 months prior to start of this study as determined by the Investigator); change in VA within previous 12 months reasonably believed to be associated with DME in the opinion of the Investigator; BCVA in accordance with ETDRS letter score of ≥ 24 (e.g., 20/320 or better) and ≤ 78 (e.g., 20/32 or worse)Exclusion Criteria: Known allergy to any danazol (Cyclomen or Danocrine) or any other non-medicinal component of the danazol test drug (cornstarch, lactose, magnesium stearate, gelatin, and talc) (Note: Lactose intolerance is not a contraindication to ingesting the small amount of lactose contained in oral medications); history of systemic (e.g., oral intravenous, intramuscular, subcutaneous, intrauterine, epidural, bursal, or implanted) androgens, progesterone or corticosteroids (including topical ophthalmic corticosteroids preparations within 4 months prior to randomization (topical non-ophthalmic corticosteroids are not excluded)Information: hloose@ampiopharma.com

Study: DRAMA: Diabetic Retinopathy And the Myvisiontrack™ App StudySponsor: Vital Art and Science IncorporatedPurpose: To determine the effect of enhancements to the myVisionTrack™ in regards to patient compliance and test-retest variabilityDesign: Observational, Case-Only, ProspectiveNumber of Patients: 100Inclusion Criteria: DR requiring treatment at time of study initiation; macular edema involving the central subfield based on clinical judgment; no noticeable central subfield atrophyExclusion Criteria: Any ocular pathology other than DR; any other concurrent systemic illness affecting the retina and visual function; dementia or other neurological or psychological limitation that would prevent patients from performing self-testing of visual functionInformation: Mike.Molai@UTSouthwestern.edu

RETINAL VEIN OCCLUSION

Study: Minocycline to Treat Branch Retinal Vein OcclusionSponsor: National Eye InstitutePurpose: To test the safety and effectiveness of minocycline as a treatment for branch retinal vein occlusionDesign: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blind, TreatmentNumber of Patients: 20Inclusion Criteria: The study eye has a best-corrected ETDRS visual acuity score between 78 and 34 letters (i.e., between 20/32 and 20/200); the study eye shows evidence of definite retinal thickening due to a BRVO based on clinical examination involving the center of the macula that is not refractory to further therapy as based on the investigator’s clinical judgment. BRVO is defined as an eye that had retinal hemorrhage or other biomicroscopic evidence of RVO (e.g., telangiectatic capillary bed) and a dilated (or previously dilated) venous system in one or two quadrants or less of the retina drained by the affected vein. Hemiretinal vein occlusion (HRVO) is an RVO that involves two altitudinal quadrants. In this study, eyes with a HRVO will be considered a BRVO and are given the same treatment as BRVO eyesExclusion Criteria: The macular edema is considered to be related to cataract extraction, or clinical examination and/or OCT suggest that vitreoretinal interface disease (e.g., a taut posterior hyaloid or epiretinal membrane) is the primary cause of the macular edema, or clinical examination, medical history and/or fluorescein angiography suggest that diabetic retinopathy is the primary cause of the edema; the study eye has a history of a recurrent RVO; the study eye has a history of RVO present for > 18 months; a brisk afferent pupillary defect (APD) is present in the study eyeInformation: meg.gordon@nih.gov

Study: Minocycline to Treat CRVOSponsor: National Eye InstitutePurpose: To test the safety and effectiveness of minocycline as a treatment for central retinal vein occlusionDesign: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blind, TreatmentNumber of Patients: 20Inclusion Criteria: The study eye has a best-corrected ETDRS visual acuity score between 78 and 34 letters (i.e., between 20/32 and 20/200); the study eye shows definite retinal thickening due to a CRVO based on clinical examination involving the center of the macula that is not refractory to further therapy as based on the investigator’s clinical judgmenExclusion Criteria: The study eye has a history of a recurrent RVO; the study eye has a history of RVO present for > 18 months

Study: ORVO: Ozurdex for RVOSponsor: Johns Hopkins University/AllerganPurpose: To measure the pro-permeability factors in the aqueous humor of patients with persistent/recurrent macular edema after an injection of OzurdexDesign: Interventional, Nonrandomized, Single-group Assignment, Open Label, TreatmentNumber of Patients: 40Inclusion Criteria: Diagnosis of macular edema due to central or BRVO; intraretinal or subretinal fluid in the maculaExclusion Criteria: Scatter laser or macular photocoagulation within 3 months of study entry in the study eye; intraocular surgery in the study eye within 3 months of study entryInformation: ghafiz1@jhmi.edu

Study: RELATE: Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein OcclusionsSponsor: Peter A. Campochiaro, MD/GenentechPurpose: To evaluate the safety and tolerability of intraocular injections of 0.5 or 2.0 mg of ranibizumab in patients with macular edema due to RVODesign: Interventional, Randomized, Safety, Parallel Assignment, Open Label, TreatmentNumber of Patients: 80Inclusion Criteria: Diagnosis of macular edema due to central or branch RVO; foveal thickness of equal to or greater than 250 mmExclusion Criteria: Scatter laser photocoagulation or macular photocoagulation within 3 months of study entry in the study eye; intraocular surgery in the study eye within 3 months of study entryInformation: ghafiz@jhmi.edu

Study: Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to RVOSponsor: Wills Eye InstitutePurpose: To compare dexamethasone implant with rescue intravitreal ranibizumab to monthly intravitreal ranibizumab for the treatment of macular edema due to RVODesign: Randomized, Efficacy, Parallel Assignment, Open Label, TreatmentNumber of Patients: 30Inclusion Criteria: Must be diagnosed within two weeks of onset of symptoms; BCVA between 20/40 and 20/320Exclusion Criteria: Patients with any history of prior intravitreal dexamethasone or anti-VEGF or grid laser

Study: Comparison of Initial Ozurdex to Avastin for Treatment of Macular Edema Caused by CRVOSponsor: Long Island Vitreoretinal ConsultantsPurpose: To compare visual improvement and total number of intraocular injections in eyes with macular edema following CRVO after initial treatment with Ozurdex or AvastinDesign: Interventional, Randomized, Efficacy, Parallel Assignment, Single-blind, TreatmentNumber of Patients: 30Inclusion Criteria: Presence of central RVO; VA between 3 and 72 letters and Snellen equivalent of 20/40 to 20/800Exclusion Criteria: History of glaucoma in the study eye with intraocular pressure >21mmHg on >1 topical medicationInformation: (631) 234-5666

Study: WAVE: Targeted Laser With Lucentis 0.5mg Verses Lucentis 0.5mg Monotherapy for Ischemic Central Vein OcclusionSponsor: Genentech/Charles C. Wykoff, MDPurpose: To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central RVO, compared to standard of careDesign: Interventional, Randomized, Safety/Efficacy, Single Group Assignment, Open Label, TreatmentNumber of Patients: 30Inclusion Criteria: Subjects with Ischemic CRVO with at least 2 consecutive monthly Intravitreal injections of anti-VEGF medications with presence of persistent edemaExclusion Criteria: IOP over 30 mm Hg; any previous retinal laser photocoagulation to the study eye; previous intravitreal injection in the study eye of any corticosteroid treatmentInformation: dmbmd@houstonretina.com

UVEITIS

Study: MCP: Safety, Tolerability and Efficacy of Intravitreal LFG316 in Patients With Multifocal Choroiditis and PanuveitisSponsor: NovartisPurpose: To assess the safety, tolerability and effect of intravitreal LFG316 in patients with active Multifocal Choroiditis and PanuveitisDesign: Interventional, Randomized, Parallel Assignment, Open Label, TreatmentNumber of Patients: 24Inclusion Criteria: Active Multifocal Choroiditis and Panuveitis in the study eye; vitrifies in the study eye of 2+ or more (on Nussenblatt scale); visual acuity (ETDRS Method) of 60 letters or less in the study eye Exclusion Criteria: Substantial abnormality in screening laboratory results or electrocardiogram; history of infectious uveitis or endophthalmitis in either eye; media opacity in the study eyeInformation:(862) 778-8300

Study: Abatacept in the Treatment of UveitisSponsor: Oregon Health and Science UniversityPurpose: To assess the safety and efficacy of abatacept in the treatment of uveitisDesign: Interventional, Randomized, Safety/Efficacy, Crossover, Double-blind, TreatmentNumber of Patients: 20Inclusion Criteria: patients with vision-threatening autoimmune uveitis; failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effectsExclusion Criteria: Serious concomitant illness that could interfere with the subject’s participationInformation: suhlere@ohsu.edu

Study: Optiquel as Corticosteroid-sparing Therapy for Chronic Noninfectious UveitisSponsor: National Eye InstitutePurpose: To evaluate the safety and effectiveness of Optiquel as a treatment for uveitisDesign: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blindNumber of Patients: 60Inclusion Criteria: Participant has been diagnosed with non-infectious unilateral or bilateral uveitis for at least three monthsExclusion Criteria: Participant has a non-iatrogenic immunodeficiency state; participant had intra-ocular surgery or intraocular injection within three months prior to randomizationInformation: dobiyor@mail.nih.gov

Study: Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious UveitisSponsor: XOMA (US), LLC/Institut de Recherches Internationales ServierPurpose: To evaluate the efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or panuveitisDesign: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blindNumber of Patients: 300Inclusion Criteria: Diagnosis of noninfectious intermediate, posterior, or pan-uveitis in at least one eye; active uveitic disease in at least one eye; currently on one of the following stable treatment regimens for uveitisExclusion Criteria: Infectious uveitis and masquerade syndromes; isolated anterior uveitis; contraindication to mydriaticsInformation: nathr@xoma.com

Study: The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory DiseaseSponsor: National Eye InstitutePurpose: To study the vitreous that will be removed from patients’ eyes during an operation to insert a steroid implantDesign: ObservationalNumber of Patients: 300Information: patti.sherry@nih.gov

Study: Efficacy and Safety of Adalimumab in Subjects With Inactive UveitisSponsor: AbbottPurpose: To compare the safety and efficacy of Adalimumab vs. Placebo in subjects with inactive uveitisDesign: Interventional, Randomized, Safety/Efficacy, Parallel Assignment, Double-blindNumber of Patients: 250Inclusion Criteria: Subject is diagnosed with non-infectious intermediate-, posterior-, or pan-uveitis; subject that for >/= 28 days prior to the Baseline visit has inactive disease and is taking >/= 10 mg of oral prednisone to maintain this inactive stateExclusion Criteria: Isolated anterior uveitis; conirmed or suspected infectious uveitisInformation: andrea.byars@abbott.com

Study: Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal MethotrexateSponsor: National Eye InstitutePurpose: To evaluate the safety and effectiveness of methotrexate as a treatment for macular edema associated with uveitisDesign: Interventional, Safety/Efficacy, Single-group Assignment, Open Label, TreatmentNumber of Patients: 7Inclusion Criteria: Chronic macular edema secondary to noninfectious panuveritis posterior or intermediate uveitis that has not been responsive to conventional immunosuppression in 3 monthsExclusion Criteria: Participant has evidence of infectious panuveritis posterior or intermediate uveitis in either eye Information: patti.sherry@nih.gov